| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 750 | $90 | $70.9K |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | 610 | $110 | $64.9K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 320 | $100 | $31.6K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 12,400 | $1 | $24.8K |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | 3,580 | $10 | $21.5K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 20,250 | $1 | $20.3K |
| J1437 | Injection, ferric derisomaltose, 10 mg | 1,200 | $20 | $19.2K |
| 99223 | The provider sees a patient for an initial hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the… | 130 | $140 | $18.5K |
| 99233 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the… | 170 | $100 | $16.3K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 110 | $140 | $15.6K |